[go: up one dir, main page]

WO2013186792A3 - Process for preparation of azilsartan medoxomil and its salts - Google Patents

Process for preparation of azilsartan medoxomil and its salts Download PDF

Info

Publication number
WO2013186792A3
WO2013186792A3 PCT/IN2013/000367 IN2013000367W WO2013186792A3 WO 2013186792 A3 WO2013186792 A3 WO 2013186792A3 IN 2013000367 W IN2013000367 W IN 2013000367W WO 2013186792 A3 WO2013186792 A3 WO 2013186792A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
salts
azilsartan medoxomil
methyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2013/000367
Other languages
French (fr)
Other versions
WO2013186792A2 (en
Inventor
Srinivasan Thirumalai Rajan
Chakilam Nagaraju
Achampeta Kodanda Ramprasad
Karamala Rama Subba Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSN Laboratories Pvt Ltd
Original Assignee
MSN Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MSN Laboratories Pvt Ltd filed Critical MSN Laboratories Pvt Ltd
Priority claimed from IN918CH2013 external-priority patent/IN2013CH00918A/en
Publication of WO2013186792A2 publication Critical patent/WO2013186792A2/en
Publication of WO2013186792A3 publication Critical patent/WO2013186792A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided processes for the preparation of (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl 2-ethoxyl- 1 - { [2 '-(5-oxo-4,5 -dihydro- 1,2,4-oxadiazol-3 -yl)biphenyl-4-yl]methyl } - 1 H-benzimidazole-7 -carboxylate, its potassium salt and polymorphs thereof.
PCT/IN2013/000367 2012-06-11 2013-06-06 Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts Ceased WO2013186792A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IN2306CH2012 2012-06-11
IN2306/CHE/2012 2012-06-11
IN918/CHE/2013 2013-03-04
IN1895/CHE/2013 2013-04-29
IN1895CH2013 2013-04-29
IN2399/CHE/2013 2013-05-31
IN2399CH2013 2013-05-31
IN2475CH2013 2013-06-06
IN2475/CHE/2013 2013-06-06
IN918CH2013 IN2013CH00918A (en) 2013-03-04 2013-06-06

Publications (2)

Publication Number Publication Date
WO2013186792A2 WO2013186792A2 (en) 2013-12-19
WO2013186792A3 true WO2013186792A3 (en) 2014-02-06

Family

ID=49758824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000367 Ceased WO2013186792A2 (en) 2012-06-11 2013-06-06 Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts

Country Status (1)

Country Link
WO (1) WO2013186792A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103709155A (en) * 2013-12-30 2014-04-09 江西制药有限责任公司 Preparation method of azilsartan
CN103664922A (en) * 2013-12-30 2014-03-26 成都天地仁和药物研究有限公司 Novel crystal-form azilsartan and preparation method for same
CN103880756B (en) * 2014-03-26 2016-06-01 四川奥邦药业有限公司 The preparation method of a kind of Azilsartan intermediate
CN104119279B (en) * 2014-05-30 2018-01-02 上海天慈生物谷生物工程有限公司 The method for preparing the carboxylic acid of 2 ethyoxyl 1 { [base of 2 ' (base of 5 carbonyl, 4,5 dihydro, 1,2,4 oxadiazole 3) xenyl 4] methyl } 1H benzimidazoles 7
CN104230910B (en) * 2014-09-16 2016-08-31 常州大学 The crystal formation of a kind of Azilsartan intermediate and the preparation method of crystal thereof
CN105669495A (en) * 2014-11-21 2016-06-15 重庆朗天制药有限公司 Novel preparation method for azilsartan and intermediate thereof
CN105753854A (en) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 New preparation method of azilsartan kamedoxomil
JP6856365B2 (en) * 2016-11-30 2021-04-07 株式会社トクヤマ Manufacturing method of azilsartan
CN109071519A (en) * 2016-01-28 2018-12-21 株式会社德山 Azilsartan and its manufacturing method
CN112110909A (en) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 Compound, preparation method, composition and application thereof
CN106986864B (en) * 2017-04-01 2020-04-28 宝鸡文理学院 A kind of preparation device and preparation method of Azisartan
CN107840827A (en) * 2017-11-06 2018-03-27 江苏中邦制药有限公司 A kind of synthetic method of Azilsartan intermediate
CN113544113B (en) 2019-01-02 2023-12-26 临海市华南化工有限公司 Synthesis method of candesartan cilexetil intermediate
CN115028589A (en) * 2022-07-21 2022-09-09 浙江普洛家园药业有限公司 Preparation method of azilsartan process impurity
CN119930599B (en) * 2025-01-24 2025-11-21 山东鲁宁药业有限公司 Preparation process of high-purity azilsartan medoxomil

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420016A1 (en) * 2001-08-03 2004-05-19 Takeda Chemical Industries, Ltd. Crystal and process for producing the same
WO2005080384A2 (en) * 2004-02-25 2005-09-01 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as aii receptor antagonist
WO2012090043A1 (en) * 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2013042067A1 (en) * 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013114305A1 (en) * 2012-02-02 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420016A1 (en) * 2001-08-03 2004-05-19 Takeda Chemical Industries, Ltd. Crystal and process for producing the same
WO2005080384A2 (en) * 2004-02-25 2005-09-01 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as aii receptor antagonist
WO2012090043A1 (en) * 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2013042067A1 (en) * 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013114305A1 (en) * 2012-02-02 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
WO2013186792A2 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
WO2013186792A3 (en) Process for preparation of azilsartan medoxomil and its salts
WO2012107814A8 (en) An improved process for the preparation of azilsartan medoxomil
ZA201500728B (en) Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
IL223002A (en) Crystalline form of 4-[5-[3-chloro-5 -(trifluoromethyl) phenyl]-4, 5- dihydro - 5 -(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2- [(2, 2, 2-trifluoroethyl)amino] ethyl]-1- naphthalenecarboxamide
HK1203497A1 (en) Non-systemic tgr5 agonists
IL211728A0 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
IL207854A0 (en) Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
HUE036953T2 (en) 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis
IL225704A0 (en) Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
EP2867230A4 (en) PROCESSES FOR THE PREPARATION OF 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLES
HUP1300730A2 (en) A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan
IL219718A0 (en) 3-(3-,4- dihydro-2h-benzo [1,4] oxazin - 6 yl) 1h-pyrimidin -2, 4 dione compounds as herbicides
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
IL208951A0 (en) Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2011014611A3 (en) Preparation of olmesartan medoxomil
WO2014085153A8 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
HUP1300733A2 (en) A method of preparing 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl- 4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylates and conversion thereof to azilsartan
WO2013088384A3 (en) Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
AP2011005999A0 (en) Process for the preparation of olmesartan medoxomil.
CL2013001518A1 (en) Compounds derived from 5- [5- (3,5-difluorophenyl) -1h-imidazol-4-yl] [1,3] oxazolo [5,4-b] pyridin-2-amine; pharmaceutical composition; pharmaceutical combination; use for use in cancer treatment, such as ovarian cancer, multiple myeloma, among others
WO2014009969A3 (en) Novel polymorphs of azilsartan
MX360291B (en) Novel salt of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]meth ylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine- 2,4-dione, preparation thereof and formulations containing same.
WO2011111971A3 (en) Method for preparing (r)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1h)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives
IN2013CH00918A (en)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13803989

Country of ref document: EP

Kind code of ref document: A2